Direkt zum Inhalt
Merck
Alle Fotos(2)

Dokumente

ABN73

Sigma-Aldrich

Anti-Neutral amino acid transporter (ASCT2) Antibody

from rabbit, purified by affinity chromatography

Synonym(e):

Neutral amino acid transporter B(0), Baboon M7 virus receptor, RD114/simian type D retrovirus receptor, Sodium-dependent neutral amino acid transporter type 2, Solute carrier family 1 member 5

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Biologische Quelle

rabbit

Qualitätsniveau

Antikörperform

affinity isolated antibody

Antikörper-Produkttyp

primary antibodies

Klon

polyclonal

Aufgereinigt durch

affinity chromatography

Speziesreaktivität

human

Methode(n)

immunohistochemistry: suitable (paraffin)
western blot: suitable

NCBI-Hinterlegungsnummer

UniProt-Hinterlegungsnummer

Versandbedingung

wet ice

Posttranslationale Modifikation Target

unmodified

Angaben zum Gen

human ... SLC1A5(6510)

Allgemeine Beschreibung

Neutral amino acid transporter, also known as ASCT2, is an alternate of the ASC (alanine-, serine-, cysteine-) transport system and is highly expressed in rat astroglia-rich cultures while not highly expressed in rat neuron-rich cultures. ASCT2 is also thought to be important in the glutamine release from cells. ASCT2 has been implicated in the growth and survival of cancer cells, therefore making it a possible target for cancer therapy. ASCT2 is thought to be a crucial neuronal neutral amino acid transporter.

Spezifität

No homology found to mouse or rat. Other homologies: rhesus monkey (93% sequence homology).
This antibody recognizes Neutral amino acid transporter at the N-terminus.

Immunogen

Epitope: N-terminus
KLH-conjugated linear peptide corresponding to the N-terminus of Neutral amino acid transporter.

Anwendung

Research Category
Neurowissenschaft
Research Sub Category
Ionenkanäle & -transporter
Anti-Neutral amino acid transporter (ASCT2) Antibody detects level of Neutral amino acid transporter (ASCT2) & has been published & validated for use in WB, IH(P).
Immunohistochemistry Analysis: 1:1000 dilution from a previous lot detected Neutral amino acid transporter in human prostate tissue.

Qualität

Evaluated by Western Blot in human placenta tissue lysate.

Western Blot Analysis: 0.5 µg/mL of this antibody detected Neutral amino acid transporter on 10 µg of human placenta tissue lysate.

Zielbeschreibung

~ 57 kDa observed

Physikalische Form

Affinity purified
Purified rabbit polyclonal in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Lagerung und Haltbarkeit

Stable for 1 year at 2-8°C from date of receipt.

Hinweis zur Analyse

Control
Human placenta tissue lysate

Sonstige Hinweise

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Lagerklassenschlüssel

12 - Non Combustible Liquids

WGK

WGK 1

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Niki M Zacharias et al.
International journal of molecular sciences, 22(6) (2021-04-04)
Von Hippel Lindau (VHL) inactivation, which is common in clear cell renal cell carcinoma (ccRCC), leads directly to the disruption of oxygen homoeostasis. VHL works through hypoxia-inducible factors (HIFs). Within this VHL-HIF system, prolyl hydroxylases (PHDs) are the intermediary proteins
Michael L Schulte et al.
Nature medicine, 24(2), 194-202 (2018-01-16)
The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine. However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date. The neutral amino acid glutamine
Patrik da Silva Vital et al.
International journal of molecular sciences, 23(24) (2022-12-24)
(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates
Da Hee Jung et al.
Life (Basel, Switzerland), 10(10) (2020-10-18)
Electroacupuncture (EA) therapy via alternating current stimulation on the scalp over the motor cortex is used for the treatment of brain disorders. Perinatal hypoxia-ischemia (HI), a brain injury in newborns, leads to long-term neurologic complications. Here, we investigated whether EA

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.